Artículos FCS INSIS

Permanent URI for this collection

https://repositoriovip.uasd.edu.do/handle/123456789/148

Browse

Browsing Artículos FCS INSIS by Author "Adrián Puello"

Now showing 1 - 3 of 3
  • Item
    (Proyecto) SARS CoV-2 en aguas residuales: una aproximación metagenómica y epidemiológica para analizar perfiles de distribución y abundancia del virus en aguas urbanas, y evaluar riesgos de dispersión ambiental en República Dominicana.
    (2026) Alfaniris Vargas; Adrián Gutiérrez; Adrián Puello; Ramón Alberto Batista García
    El diagnóstico clínico del nuevo coronavirus ha tomado gran atención en los últimos tiempos, sin embargo muy poca atención se ha prestado al monitoreo del virus en matrices que constituyen residuos de diferente naturaleza. Ha sido bien documentado que, los microorganismos y los virus tienen una amplia distribución en matrices ambientales acuosas, sólidas y aéreas. La presente propuesta se inserta en los lineamientos nacionales de la vigilancia epidemiológica del país para la contingencia sanitaria por el nuevo coronavirus SARS Cov-2. La situación sanitaria internacional, junto al escenario regional y el curso de la epidemia en República Dominicana demandan estrategias nacionales de integración para abordar la epidemia de COVD19 desde frente transversales y multidisciplinares que permitan instalar respuestas nacionales y abordajes epidemiológicos para prevenir la diseminación del virus y frenar el progreso de la enfermedad en el contexto nacional. En este proyecto se propone la vigilancia ambiental del nuevo coronavirus empleando metagenómica shotgun para muestras de aguas residuales y biosólidos municipales. Este proyecto además, permitirá, por primera vez en el país, aplicar modelos epidemiológicos para el virus (y también para enfermedades respiratorias) a partir de monitoreos ambientales. El objetivo general de este proyecto es: Analizar mediante estudios metagenómicos las poblaciones de SARS Cov-2 en muestras de aguas residuales para conocer los patrones ambientales de distribución y abundancia del virus, así como para predecir modelos epidemiológicos que contribuyan a conocer sus patrones de dispersión. Será el primer estudio metagenómico enfocado a virus en República Dominicana.
  • Item
    Real World KINDLE-Latin America Subset data on treatment patterns and clinical outcomes in patients with stage III Non-Small-Cell Lung Cancer
    (2022-07-04) Adrián Puello
    Introduction: Stage III non- small- cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real- world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from the pre- immuno- oncology era.Methods: The study was conducted in seven countries (Argentina, Chile, Colombia, Dominican Republic, Mexico, Peru and Uruguay) in stage III NSCLC (American Joint Committee on Cancer, 7th edition) diagnosed between January 2013 and December 2017. Retrospective data from patients’ medical records (index date to the end of follow- up) were collected. Summary statistics, Kaplan– Meier sur-vival estimates and a two- sided 95% confidence interval (CI) were provided. Cox proportional hazard model was used for univariate and multi- variateanalyses.Results: A total of 231 patients was enrolled, the median age was 65.0 years (range 21.0– 89.0), 60.6% were males, 76.6% had smoking history, 64.0% had ad-enocarcinoma and 28.7% underwent curative resection. Multiple treatment regi-mens (>25) were used; chemotherapy alone was the most common (24.8%). The overall median progression- free survival (mPFS) and median overall survival (mOS) were 14.8 months (95% CI, 12.1– 18.6) and 48.6 months (95% CI, 34.7 to not calculable). Significantly better mPFS and mOS were observed for stage IIIA with curative surgery and resectabletumours and stage IIIB with an Eastern Cooperative Oncology Group score of 0/1, female gender, resectabletumours, ad-enocarcinoma and curative surgery (p < 0.05).Conclusion: Results show diversity in treatment practices and the correspond-ing clinical outcomes in stage III NSCLC. There is a need to streamline treatment selection and sequencing to decrease relapse rates after initial therapy.
  • Item
    Real World KINDLE-Latin America Subset data on treatment patterns and clinical outcomes in patients with stage III non-small-cell lung cancer.
    (2023-07-04) Adrián Puello
    Introduction: Stage III non- small- cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real- world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from the pre- immuno- oncology era.Methods: The study was conducted in seven countries (Argentina, Chile, Colombia, Dominican Republic, Mexico, Peru and Uruguay) in stage III NSCLC (American Joint Committee on Cancer, 7th edition) diagnosed between January 2013 and December 2017. Retrospective data from patients' medical records (index date to the end of follow- up) were collected. Summary statistics, Kaplan– Meier sur-vival estimates and a two- sided 95% confidence interval (CI) were provided. Cox proportional hazard model was used for univariate and multi- variate analyses.Results: A total of 231 patients was enrolled, the median age was 65.0 years (range 21.0– 89.0), 60.6% were males, 76.6% had smoking history, 64.0% had ad-enocarcinoma and 28.7% underwent curative resection. Multiple treatment regi-mens (>25) were used; chemotherapy alone was the most common (24.8%). The overall median progression- free survival (mPFS) and median overall survival (mOS) were 14.8 months (95% CI, 12.1– 18.6) and 48.6 months (95% CI, 34.7 to not calculable). Significantly better mPFS and mOS were observed for stage IIIA with curative surgery and resectable tumours and stage IIIB with an Eastern Cooperative Oncology Group score of 0/1, female gender, resectable tumours, ad-enocarcinoma and curative surgery (p < 0.05).Conclusion: Results show diversity in treatment practices and the correspond-ing clinical outcomes in stage III NSCLC. There is a need to streamline treatment selection and sequencing to decrease relapse rates after initial therapy